NAYA Biosciences Inc - NAYA EV/Sales Multiple

Public company logo of NAYA Biosciences Inc. (NAYA)

NAYA Biosciences develops oncology drugs through partnerships with medical centers. The GURU.Markets terminal displays an enterprise value-to-revenue chart, where the value represents the latest figure. NAYA Biosciences seeks alternatives to chemotherapy by activating NK cells. The current R&D stage precludes commercial revenue, shifting business scaling into the realm of increasing fixed costs for scientific research.

NAYA Biosciences Corp - NAYA EV/Sales Multiple (period 07/04/2022 - 11/20/2026)

NAYA (nayabiosciences.com): analytical breakdowns and indicator data

Initial company analysis:NAYA (NAYA Biosciences)
Original product of NAYA Biosciences

For NAYA Biosciences, which is developing the Flex-NK platform for targeted immunotherapy of solid tumors, the potential for technology commercialization serves as a key valuation factor. By analyzing the ratio of Enterprise Value to revenue, an investor can view the market value of the entire business, including net debt, relative to sales, which allows for an assessment of the premium for future growth and the risk of overpayment within M&A transactions.

Competitor analysis for NAYA Biosciences

Enterprise Value-to-Sales Ratio BeiGene Ltd (ONC)|Halozyme Corp (HALO) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Revolution Medicines Inc (RVMD)|Enterprise Value-to-Revenue Ratio Ascentage Pharma Group|Company Value to Revenue Ratio CGON (CG Oncology Corp)|Enterprise Value-to-Revenue Ratio UroGen Pharma (URGN)|EV/Sales Multiple Bicara Therapeutics (BCAX)|EV/Sales Multiple PSNL (personalis.com)|Business Value to Revenue ERAS|DCTH: Company Value to Revenue|YmAbs - Enterprise Value-to-Revenue Coefficient|aurabiosciences.com (AURA) - Enterprise Value-to-Revenue Ratio|Candel Therapeutics Inc. - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Accuray Inc.|Enterprise Value-to-Revenue Multiple SELLAS Life Sciences Group SLS|EV/Sales Multiple ACTU|CTOR - Enterprise Value-to-Revenue Multiple|EV/Sales Multiple HURA (TuHURA Biosciences, Inc.)|Business Value to Revenue TARA|FATE: Company Value to Revenue|WHWK (aadibio.com) - Company Value to Revenue Ratio|TCRX (TScan Therapeutics, Inc.) - Company Value to Revenue|Enterprise Value-to-Revenue Multiple Champions Oncology Corp (CSBR)|XBIT (XBiotech Inc.) - EV/Sales Multiple|CVM (CEL-SCI Corporation) - Enterprise Value-to-Revenue Coefficient|EV/Sales Multiple OSTX|EV/Sales Multiple Radiopharm Theranostics Ltd (RADX)|EV/Sales Multiple ARTV (Artiva Biotherapeutics)|EV/Sales Multiple Adlai Nortye Ltd. ANL|Veru Inc - EV/Sales Multiple|Total Company Value-to-Revenue Ratio Tempest Therapeutics TPST|XLO: EV/Sales Multiple|Enochian BioSciences (RENB) - EV/Sales Multiple|Company Value to Revenue MURA|Kairos Pharma Ltd - Enterprise Value to Sales Volume|EV/Sales Multiple OKUR|CytoMed Therapeutics Limited (GDTC) - Enterprise Value-to-Sales Ratio|EV/Sales Multiple CRIS (Curis, Inc.)|APLM: Company Value to Revenue Ratio|Tharimmune Corporation - EV/Sales Multiple|ADVB: Enterprise Value-to-Revenue Ratio|GNPX: EV/Sales Multiple|CLDI (Calidi Biotherapeutics Inc.) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Sunshine Biopharma, Inc.|EV/Sales Multiple xeneticbio.com|Enterprise Value-to-Revenue Ratio Salarius (SLRX)|Company Value to Revenue Purple Biotech PPBT|Enterprise Value-to-Revenue Ratio American Oncology Network, Inc. AONC|BeiGene, Ltd. (BGNE) - Enterprise Value-to-Revenue Multiple|Checkpoint Therapeutics Inc. - EV/Sales Multiple|Business Value to Revenue ELEV (Elevation Oncology)|ICAD (iCAD Corp) - Company Value to Revenue|Ikena Oncology, Inc. - Business Value to Revenue|Company Value to Revenue NTBL|VIRX: Business Value to Revenue|Enterprise Value-to-Revenue Ratio MorphoSys Corporation (MOR)|Ascentage Pharma - Company Value to Revenue Ratio